On December 28, the Shenzhen Stock Exchange** disclosed that Beijing Simiric Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Simric") applied for withdrawal of the issuance and listing application documents on December 22, 2023. In accordance with Article 62 of the Rules for the Review of the Issuance and Listing of the Shenzhen Stock Exchange, the Shenzhen Stock Exchange has decided to terminate the review of its initial public offering** and listing on the GEM.
Simrike is a pharmaceutical R&D contract research organization with professional service capabilities such as large-sample, multi-center clinical trial operation, data management and statistical analysis, and is committed to providing industry-leading integrated R&D service platform and innovative solutions for clinical research across the whole cycle for biopharmaceutical companies mainly in the fields of vaccines, chronic diseases, infectious diseases and other diseases, covering vaccine preclinical process exploration and optimization, clinical trial design and operation, clinical trial data management and statistical analysis, product listing registration services, etc.
According to the prospectus, from 2020 to 2022, the operating income of Simiric will be about 18.8 billion yuan, 27.5 billion yuan, 36.8 billion yuan;The corresponding net profit was 2773720,000 yuan, 6179340,000 yuan and 8713360,000 yuan.
In this IPO, Simiric originally planned to raise 6500 million yuan, which will be used for the construction of the clinical monitoring service platform, the vaccine R&D center of Simrike and the replenishment of working capital.
Synthesized from the announcement of the Shenzhen Stock Exchange and the company's prospectus).